Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Juan Madoz-Gúrpide"'
Autor:
Iris Garrido‐Cano, Anna Adam‐Artigues, Ana Lameirinhas, Juan F. Blandez, Vicente Candela‐Noguera, Federico Rojo, Sandra Zazo, Juan Madoz‐Gúrpide, Ana Lluch, Begoña Bermejo, Felix Sancenón, Juan Miguel Cejalvo, Ramón Martínez‐Máñez, Pilar Eroles
Publikováno v:
Cancer Communications, Vol 42, Iss 12, Pp 1412-1416 (2022)
Externí odkaz:
https://doaj.org/article/7c968fc3805d4bed95fdb0851caa2240
Autor:
Marta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego, Ion Cristóbal, Natalia Ramírez-Merino, Yamileth Rangel, Yann Izarzugaza, Pilar Eroles, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 1, p 207 (2023)
The combination of trastuzumab and pertuzumab as first-line therapy in patients with HER2-positive breast cancer has shown significant clinical benefits compared to trastuzumab alone. However, despite initial therapeutic success, most patients eventu
Externí odkaz:
https://doaj.org/article/bc12f861f9384387a8568388f68dc386
Autor:
Andrea Santos, Ion Cristóbal, Cristina Caramés, Melani Luque, Marta Sanz-Álvarez, Juan Madoz-Gúrpide, Federico Rojo, Jesús García-Foncillas
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 7779 (2023)
MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker of patient recurrence and pathologic
Externí odkaz:
https://doaj.org/article/0f2c2e61012e4c7dafc07870aa31a634
Autor:
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3601 (2023)
Due to the lack of specific targets, cytotoxic chemotherapy still represents the common standard treatment for triple-negative breast patients. Despite the harmful effect of chemotherapy on tumor cells, there is evidence that treatment could modulate
Externí odkaz:
https://doaj.org/article/58fb6b02a97b494abfaa2932b5aa3d4a
Autor:
Andrea Santos, Ion Cristóbal, Jaime Rubio, Cristina Caramés, Melani Luque, Marta Sanz-Álvarez, Sandra Zazo, Juan Madoz-Gúrpide, Federico Rojo, Jesus García-Foncillas
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 20, p 12447 (2022)
The standard clinical management of locally advanced rectal cancer (LARC) patients includes neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) followed by mesorectal excision. MicroRNA (miR)-19b expression levels in LARC biopsies obtaine
Externí odkaz:
https://doaj.org/article/d4c3f7b9189b48418f801bf9a4d9b2dc
Autor:
Andrea Santos, Ion Cristóbal, Jaime Rubio, Cristina Caramés, Melani Luque, Marta Sanz-Alvarez, Miriam Morales-Gallego, Juan Madoz-Gúrpide, Federico Rojo, Jesús García-Foncillas
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 4, p 2203 (2022)
The identification of robust prognostic markers still represents a need in locally advanced rectal cancer (LARC). MicroRNAs (miRs) have progressively emerged as promising circulating markers, overcoming some limitations that traditional biopsy compri
Externí odkaz:
https://doaj.org/article/07e4b92d14354682a84b34289bcb034a
Autor:
Melani Luque, Marta Sanz-Álvarez, Andrea Santamaría, Sandra Zazo, Ion Cristóbal, Lorena de la Fuente, Pablo Mínguez, Pilar Eroles, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 24, p 13297 (2021)
The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel alone. However, despite th
Externí odkaz:
https://doaj.org/article/9b169629af9045668958521f5e012d9f
Autor:
Paula González-Alonso, Cristina Chamizo, Víctor Moreno, Juan Madoz-Gúrpide, Nerea Carvajal, Lina Daoud, Sandra Zazo, Ester Martín-Aparicio, Ion Cristóbal, Raúl Rincón, Jesús García-Foncillas, Federico Rojo
Publikováno v:
International Journal of Molecular Sciences, Vol 16, Iss 8, Pp 19447-19457 (2015)
Mutations in Human Epidermal Growth Factor Receptors (HER) are associated with poor prognosis of several types of solid tumors. Although HER-mutation detection methods are currently available, such as Next-Generation Sequencing (NGS), alternative pyr
Externí odkaz:
https://doaj.org/article/f763525e464e42e3a6ae653c146b99ab
Autor:
Ion Cristóbal, Paula González-Alonso, Lina Daoud, Esther Solano, Blanca Torrejón, Rebeca Manso, Juan Madoz-Gúrpide, Federico Rojo, Jesús García-Foncillas
Publikováno v:
Marine Drugs, Vol 13, Iss 6, Pp 3276-3286 (2015)
Protein phosphatase 2A (PP2A) is a tumor suppressor complex that has recently been reported as a novel and highly relevant molecular target in prostate cancer (PCa). However, its potential therapeutic value remains to be fully clarified. We treated P
Externí odkaz:
https://doaj.org/article/fc737634dcf647f3b92be0eba3f1b1f6
Autor:
Jesús García-Foncillas, Federico Rojo, Juan Madoz-Gúrpide, Oscar Aguilera, Sandra Zazo, María Rodriguez, Javier Martínez-Useros, Aurea Borrero, Clara Senin, Cristina Caramés, Raúl Rincón, Rebeca Manso, Ion Cristóbal
PDF - 124K, Supplementary Table 1. Clinical and molecular characteristics of the 21 patients with CRC included in the study. Supplementary Table 2. Analysis of PP2A activity levels using 1D6 or FL-309 antibodies, SET overexpression, CIP2A overexpress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da5d05fd028477acdfd7b8ffda15229
https://doi.org/10.1158/1535-7163.22499598
https://doi.org/10.1158/1535-7163.22499598